Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis
Benjamin E. Decato, Diana Julie Leeming, Jannie Marie Bülow Sand, et al.
Respiratory Research (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Emerging Roles of Lysophosphatidic Acid in Macrophages and Inflammatory Diseases
S Jiang, Hui‐Li Yang, Ming‐Qing Li
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12524-12524
Open Access | Times Cited: 14
Pharmacokinetics of Fipaxalparant, a Small‐Molecule Selective Negative Allosteric Modulator of Lysophosphatidic Acid Receptor 1, and the Effect of Food in Healthy Volunteers
Yang Song, Farah N. Ali, Ye Zhan, et al.
Clinical Pharmacology in Drug Development (2024) Vol. 13, Iss. 7, pp. 819-827
Open Access | Times Cited: 5
Downregulation of HMGCS2 mediated AECIIs lipid metabolic alteration promotes pulmonary fibrosis by activating fibroblasts
Juntang Yang, Xin Pan, Min Xu, et al.
Respiratory Research (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 4
The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective anti-fibrotic and anti-inflammatory activity in different models of pulmonary fibrosis.
Magdalena Birker, Maxime Boucher, Giuseppe Ranieri, et al.
Journal of Pharmacology and Experimental Therapeutics (2025) Vol. 392, Iss. 3, pp. 103396-103396
Closed Access
Generation of New Knock-Out Mouse Strains of Lysophosphatidic Acid Receptor 1
Georgia Antonopoulou, Christiana Magkrioti, Ismini Chatzidaki, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2811-2811
Open Access
Advances and future outlook in clinical trials for treating systemic sclerosis-interstitial lung disease
Marzieh Jamali, R Vázquez‐Sánchez, Prachi Agarwal, et al.
Expert Review of Respiratory Medicine (2025)
Closed Access
Autotaxin in Breast Cancer: Role, Epigenetic Regulation and Clinical Implications
Andrianna Drosouni, Μαρία Παναγοπούλου, Vassilis Aidinis, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5437-5437
Open Access | Times Cited: 16
Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases
Cyrille Lescop, Magdalena Birker, Christine Brotschi, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2397-2424
Closed Access | Times Cited: 3
Understanding myofibroblast origin in the fibrotic lung
Mahsa Zabihi, Mahtab Shahriari Felordi, Arun Lingampally, et al.
Chinese Medical Journal - Pulmonary and Critical Care Medicine (2024) Vol. 2, Iss. 3, pp. 142-150
Open Access | Times Cited: 3
Designing Dual Inhibitors of Autotaxin-LPAR GPCR Axis
Souvik Banerjee, Sue-Chin Lee, Derek D. Norman, et al.
Molecules (2022) Vol. 27, Iss. 17, pp. 5487-5487
Open Access | Times Cited: 13
Lysophosphatidylcholine acyltransferase 1 alleviates silica-induced pulmonary fibrosis by modulating lipid metabolism
Xuedan Deng, Changfu Hao, Yiping Li, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 155, pp. 113638-113638
Open Access | Times Cited: 11
Diagnosis of Fibrotic Hypersensitivity Pneumonitis: Is There a Role for Biomarkers?
João Pereira, V. Fernandes, Tiago M. Alfaro, et al.
Life (2023) Vol. 13, Iss. 2, pp. 565-565
Open Access | Times Cited: 6
Single-cell transcriptome dynamics of the autotaxin-lysophosphatidic acid axis during muscle regeneration reveal proliferative effects in mesenchymal fibro-adipogenic progenitors
Osvaldo Contreras, Richard P. Harvey
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 6
Lysophosphatidic Acid Receptor Signaling in the Human Breast Cancer Tumor Microenvironment Elicits Receptor-Dependent Effects on Tumor Progression
Matthew G.K. Benesch, Rongrong Wu, Xiaoyun Tang, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 9812-9812
Open Access | Times Cited: 6
Recent progress on tyrosine kinase 2 JH2 inhibitors
Lidan Deng, Li Wan, Tingting Liao, et al.
International Immunopharmacology (2023) Vol. 121, pp. 110434-110434
Closed Access | Times Cited: 6
Type IV collagen
Jannie Marie Bülow Sand, S.F. Madsen, M.A. Karsdal
Elsevier eBooks (2024), pp. 37-53
Closed Access | Times Cited: 2
Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold
Cyrille Lescop, Christine Brotschi, Jodi T. Williams, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2379-2396
Closed Access | Times Cited: 2
Pulmonary Fibrosis and Diabetes Mellitus: Two coins with the same face
Yssel Mendoza‐Marí, Marcel Fraix, Devendra K. Agrawal
Archives of Internal Medicine Research (2024) Vol. 07, Iss. 01
Open Access | Times Cited: 2
Specneuzhenide improves bleomycin-induced pulmonary fibrosis in mice via AMPK-dependent reduction of PD-L1
Yanliang Wu, Wen Shi, Haini Li, et al.
Phytomedicine (2023) Vol. 128, pp. 155318-155318
Closed Access | Times Cited: 5
A serologically assessed neo-epitope biomarker of cellular fibronectin degradation is related to pulmonary fibrosis
Annika Hummersgaard Hansen, Helene W. Breisnes, Thomas Skovhus Prior, et al.
Clinical Biochemistry (2023) Vol. 118, pp. 110599-110599
Open Access | Times Cited: 4
Emerging opportunities to treat idiopathic pulmonary fibrosis: Design, discovery, and optimizations of small-molecule drugs targeting fibrogenic pathways
Wenxin Luo, Yilin Gu, Siyu Fu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115762-115762
Closed Access | Times Cited: 4
ISABELA Studies: Plasma Exposure and Target Engagement Do Not Explain the Lack of Efficacy of Ziritaxestat in Patients with Idiopathic Pulmonary Fibrosis
Amit Taneja, Garrit Jentsch, Stéphane Delage, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 115, Iss. 3, pp. 606-615
Open Access | Times Cited: 4
Lysophosphatidic Acid-Mediated Inflammation at the Heart of Heart Failure
Rajesh Chaudhary, Tahra K. Suhan, Mahmud W. Tarhuni, et al.
Current Cardiology Reports (2024) Vol. 26, Iss. 3, pp. 113-120
Open Access | Times Cited: 1
The Role of Lysophospholipid Metabolites LPC and LPA in the Pathogenesis of Chronic Obstructive Pulmonary Disease
Qiqiang Zhou, Yahong Chen, Ying Liang, et al.
Metabolites (2024) Vol. 14, Iss. 6, pp. 317-317
Open Access | Times Cited: 1
Unveiling the therapeutic promise: exploring Lysophosphatidic Acid (LPA) signaling in malignant bone tumors for novel cancer treatments
Yichen Qi, Yukai Wang, Jinping Yuan, et al.
Lipids in Health and Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top